H. Lundbeck A/S
HLUN-A
Rankning i aktier
#3070
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aktiekurs
$7.07
Marknadsvärde
$5.91B
Förändring (1 dag)
-4.56%
Förändring (1 år)
28.57%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Kategori
Healthcare
Antal utestående aktier för H. Lundbeck A/S (HLUN-A)
Antal utestående aktier per June 2026: 992.15M
Enligt de senaste finansiella rapporterna och aktiekursen för H. Lundbeck A/S är det aktuella antalet utestående aktier 992.15M. I slutet av December 2024 hade företaget 991.44M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för H. Lundbeck A/S (HLUN-A) från 2004 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 992.15M | 0.00% |
| 2025 | 992.15M | 0.07% |
| 2024 | 991.44M | -0.08% |
| 2023 | 992.24M | -0.06% |
| 2022 | 992.87M | 24.94% |
| 2021 | 794.64M | 299.92% |
| 2020 | 198.70M | 0.01% |
| 2019 | 198.69M | 0.01% |
| 2018 | 198.68M | 0.59% |
| 2017 | 197.51M | 0.17% |
| 2016 | 197.19M | 0.36% |
| 2015 | 196.47M | 0.11% |
| 2014 | 196.25M | 0.06% |
| 2013 | 196.14M | 0.00% |
| 2012 | 196.13M | 0.01% |
| 2011 | 196.10M | -0.01% |
| 2010 | 196.12M | 0.00% |
| 2009 | 196.12M | -0.37% |
| 2008 | 196.84M | -3.97% |
| 2007 | 204.99M | -2.89% |
| 2006 | 211.10M | -6.00% |
| 2005 | 224.56M | -2.20% |
| 2004 | 229.61M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 445.06M | -55.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 105.38M | -89.38% |
US
|
|
| - | - |
IT
|
